Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) – William Blair decreased their Q4 2022 EPS estimates for shares of Jasper Therapeutics in a report issued on Monday, January 30th. William Blair analyst M. Phipps now anticipates that the company will earn ($0.34) per share for the quarter, down from their previous forecast of ($0.31). The consensus estimate for Jasper Therapeutics' current full-year earnings is ($1.34) per share. William Blair also issued estimates for Jasper Therapeutics' Q1 2023 earnings at ($0.14) EPS, Q2 2023 earnings at ($0.12) EPS, Q3 2023 earnings at ($0.13) EPS, Q4 2023 earnings at ($0.13) EPS, FY2023 earnings at ($0.52) EPS, FY2024 earnings at ($0.54) EPS, FY2025 earnings at ($0.60) EPS and FY2026 earnings at ($0.55) EPS.
Get Jasper Therapeutics alerts:JSPR has been the topic of a number of other reports. Credit Suisse Group lowered their price target on shares of Jasper Therapeutics from $7.00 to $3.00 and set an "outperform" rating on the stock in a report on Wednesday, January 11th. EF Hutton Acquisition Co. I reissued a "buy" rating and set a $4.00 price target on shares of Jasper Therapeutics in a report on Wednesday, January 11th. Finally, Oppenheimer lowered their price target on shares of Jasper Therapeutics from $21.00 to $8.00 and set an "outperform" rating on the stock in a report on Monday, November 14th.
Jasper Therapeutics Price Performance
Shares of NASDAQ JSPR opened at $1.65 on Wednesday. The company's fifty day moving average price is $1.11 and its 200 day moving average price is $1.26. Jasper Therapeutics has a 1 year low of $0.39 and a 1 year high of $5.81.Jasper Therapeutics (NASDAQ:JSPR – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03.
Institutional Investors Weigh In On Jasper Therapeutics
A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new stake in shares of Jasper Therapeutics in the first quarter valued at about $39,000. State Street Corp raised its position in shares of Jasper Therapeutics by 51.2% in the second quarter. State Street Corp now owns 32,884 shares of the company's stock valued at $63,000 after buying an additional 11,132 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Jasper Therapeutics by 10.3% in the third quarter. Vanguard Group Inc. now owns 530,120 shares of the company's stock valued at $418,000 after buying an additional 49,559 shares during the last quarter. Forefront Analytics LLC raised its position in shares of Jasper Therapeutics by 246.0% in the third quarter. Forefront Analytics LLC now owns 119,800 shares of the company's stock valued at $94,000 after buying an additional 85,175 shares during the last quarter. Finally, Citadel Advisors LLC increased its position in Jasper Therapeutics by 3.8% during the third quarter. Citadel Advisors LLC now owns 3,102,016 shares of the company's stock worth $2,448,000 after purchasing an additional 112,913 shares during the last quarter. 68.37% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, major shareholder Carlyle Group Inc. acquired 3,133,333 shares of Jasper Therapeutics stock in a transaction on Friday, January 27th. The stock was bought at an average cost of $1.50 per share, for a total transaction of $4,699,999.50. Following the completion of the transaction, the insider now owns 8,761,891 shares of the company's stock, valued at approximately $13,142,836.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Carlyle Group Inc. acquired 3,133,333 shares of Jasper Therapeutics stock in a transaction on Friday, January 27th. The stock was bought at an average cost of $1.50 per share, for a total transaction of $4,699,999.50. Following the completion of the transaction, the insider now owns 8,761,891 shares of the company's stock, valued at approximately $13,142,836.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Holding Ltd Roche sold 75,000 shares of the company's stock in a transaction on Wednesday, January 25th. The stock was sold at an average price of $1.89, for a total transaction of $141,750.00. Following the transaction, the insider now owns 4,549,606 shares of the company's stock, valued at $8,598,755.34. The disclosure for this sale can be found here. 22.00% of the stock is currently owned by company insiders.
About Jasper Therapeutics
(Get Rating)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
Read More
- Get a free copy of the StockNews.com research report on Jasper Therapeutics (JSPR)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.